These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 30898450)

  • 1. Epidemiology of hyperkalemia in chronic kidney disease.
    Belmar Vega L; Galabia ER; Bada da Silva J; Bentanachs González M; Fernández Fresnedo G; Piñera Haces C; Palomar Fontanet R; Ruiz San Millán JC; de Francisco ÁLM
    Nefrologia (Engl Ed); 2019; 39(3):277-286. PubMed ID: 30898450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maintaining Renin-Angiotensin-Aldosterone System Inhibitor Treatment with Patiromer in Hyperkalaemic Chronic Kidney Disease Patients: Comparison of a Propensity-Matched Real-World Population with AMETHYST-DN.
    Chinnadurai R; Rengarajan S; Budden JJ; Quinn CM; Kalra PA
    Am J Nephrol; 2023; 54(9-10):408-415. PubMed ID: 37725919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic impact of the use of patiromer in chronic kidney disease or heart failure for the treatment of chronic hyperkalemia in Spain.
    de Sequera P; Bover R; Ivanova-Markova Y; Ivanova A; González-Domínguez A; Valls M; Campos V
    Nefrologia (Engl Ed); 2023; 43(6):721-730. PubMed ID: 38228463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The value of maintaining normokalaemia and enabling RAASi therapy in chronic kidney disease.
    Evans M; Palaka E; Furuland H; Bennett H; Linde C; Qin L; McEwan P; Bakhai A
    BMC Nephrol; 2019 Jan; 20(1):31. PubMed ID: 30704421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The LIFT trial: study protocol for a double-blind, randomised, placebo-controlled trial of K
    Murphy D; Ster IC; Kaski JC; Anderson L; Banerjee D
    BMC Nephrol; 2021 Jul; 22(1):254. PubMed ID: 34229607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cost-effectiveness analysis of patiromer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failure.
    Ward T; Lewis RD; Brown T; Baxter G; de Arellano AR
    BMC Nephrol; 2023 Mar; 24(1):47. PubMed ID: 36890464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of hyperkalemia and RAASi nonadherence on patients affected by heart failure or chronic kidney disease].
    Degli Esposti L; Perrone V; Giacomini E; Sangiorgi D; Alessandrini D; Santoro A
    G Ital Nefrol; 2019 Sep; 36(5):. PubMed ID: 31580544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum potassium as a predictor of adverse clinical outcomes in patients with chronic kidney disease: new risk equations using the UK clinical practice research datalink.
    Furuland H; McEwan P; Evans M; Linde C; Ayoubkhani D; Bakhai A; Palaka E; Bennett H; Qin L
    BMC Nephrol; 2018 Aug; 19(1):211. PubMed ID: 30134846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Consensus on the management of hyperkalemia in patients with heart failure: Recommendations from the SEC-SEMI.
    Almenar Bonet L; González-Franco Á;
    Rev Clin Esp (Barc); 2022 Apr; 222(4):235-240. PubMed ID: 34348884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and Economic Impact of Hyperkalemia in Patients with Chronic Kidney Disease and Heart Failure.
    Polson M; Lord TC; Kangethe A; Speicher L; Farnum C; Brenner M; Oestreicher N; Alvarez P
    J Manag Care Spec Pharm; 2017 Apr; 23(4-a Suppl):S2-S9. PubMed ID: 28436256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence, clinical impact and costs of hyperkalaemia: Special focus on heart failure.
    Maggioni AP; Dondi L; Andreotti F; Calabria S; Iacoviello M; Gorini M; Gonzini L; Piccinni C; Ronconi G; Martini N
    Eur J Clin Invest; 2021 Aug; 51(8):e13551. PubMed ID: 33786826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Classical nephroprotection: Renin angiotensin aldosterone system inhibitors].
    Egocheaga MI; Drak Y; Otero V
    Semergen; 2023 Jun; 49 Suppl 1():102018. PubMed ID: 37355297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Changes in Creatinine and Potassium Levels After Initiation of Renin Angiotensin Aldosterone System Inhibitors With Emergency Department Visits, Hospitalizations, and Mortality in Individuals With Chronic Kidney Disease.
    Garlo KG; Bates DW; Seger DL; Fiskio JM; Charytan DM
    JAMA Netw Open; 2018 Nov; 1(7):e183874. PubMed ID: 30646338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between hyperkalemia, RAASi non-adherence and outcomes in chronic kidney disease.
    Santoro A; Perrone V; Giacomini E; Sangiorgi D; Alessandrini D; Degli Esposti L
    J Nephrol; 2022 Mar; 35(2):463-472. PubMed ID: 34115311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperkalemia and renin-angiotensin aldosterone system inhibitor therapy in chronic kidney disease: A general practice-based, observational study.
    Jun M; Jardine MJ; Perkovic V; Pilard Q; Billot L; Rodgers A; Rogers K; Gallagher M
    PLoS One; 2019; 14(3):e0213192. PubMed ID: 30845156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes in patients with cardiometabolic disease who develop hyperkalemia while treated with a renin-angiotensin-aldosterone system inhibitor.
    Johnson M; Morrison FJ; McMahon G; Su M; Turchin A
    Am Heart J; 2023 Apr; 258():49-59. PubMed ID: 36642227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of hyperkalemia with clinical outcomes in advanced chronic kidney disease.
    Caravaca-Fontán F; Valladares J; Díaz-Campillejo R; Barroso S; Luna E; Caravaca F
    Nefrologia (Engl Ed); 2019; 39(5):513-522. PubMed ID: 31027897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World Associations of Renin-Angiotensin-Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New-Onset Chronic Kidney Disease or Heart Failure in the United Kingdom.
    Linde C; Bakhai A; Furuland H; Evans M; McEwan P; Ayoubkhani D; Qin L
    J Am Heart Assoc; 2019 Nov; 8(22):e012655. PubMed ID: 31711387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patiromer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial.
    Butler J; Anker SD; Siddiqi TJ; Coats AJS; Dorigotti F; Filippatos G; Friede T; Göhring UM; Kosiborod MN; Lund LH; Metra M; Moreno Quinn C; Piña IL; Pinto FJ; Rossignol P; Szecsödy P; Van Der Meer P; Weir M; Pitt B
    Eur J Heart Fail; 2022 Jan; 24(1):230-238. PubMed ID: 34800079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors Secondary to Hyperkalemia Translates into Higher Cardiorenal Outcomes.
    An J; Zhou H; Ni L; Harrision TN; Wei R; Agiro A; Brahmbhatt YG; Oluwatosin Y; Schilling CG; Sim JJ
    Am J Nephrol; 2023; 54(7-8):258-267. PubMed ID: 37231821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.